Ubiquitx Inc.

Ubiquitx Inc. is a New York-based for-profit small business focused on developing innovative therapeutic technologies using advanced protein engineering and computational design. The company specializes in creating modular, programmable platforms for targeted protein modification and therapeutic interventions, with a particular emphasis on developing solutions for challenging medical conditions. Through federal contract and grant awards, Ubiquitx delivers cutting-edge research and development services primarily in the biotechnology and pharmaceutical research domains, leveraging artificial intelligence, protein engineering, and mRNA therapeutic technologies.

The company's federal contract award history includes a $354,908 firm fixed price contract from the Department of Health and Human Services' National Cancer Institute. This specific contract supports the development of the Ubiquibody Platform for Targeted Degradation of Oncogenic Fusion Proteins, focusing on demonstrating technical feasibility and proof-of-concept for therapeutic technology aimed at targeting pediatric and rare cancer-causing fusion proteins. The contract was designated as a total small business set-aside award, highlighting Ubiquitx's status as a small business enterprise, and the work is being performed in New York through February 2025.

Ubiquitx has secured multiple federal grant awards from agencies including the National Science Foundation, National Institute on Alcohol Abuse and Alcoholism, and National Institute of Allergy and Infectious Diseases. These grants, ranging from $275,000 to $391,495, support the company's development of its Chimeric Ligands for Induced Proximity (CLIPS) platform technology. The grant-funded projects focus on diverse therapeutic applications, including targeted proteome editing to treat severe alcoholic hepatitis, enhancing immune targeting of diseased cells by upregulating antigen presentation, and developing computational protein degraders for intracellular protein modification. The research aims to address critical medical challenges by creating programmable therapeutic platforms that can modify proteins of interest using advanced computational design, protein engineering, and mRNA therapeutic approaches.